Abstract: Provided herein are methods of treating and preventing pancreatitis, such as pancreatitis induced by glucagon-like peptide (GLP) agonists (such as GLP-1 agonists, for example Byetta®), by administration of a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors). In some examples the subject has diabetes, such as type 2 diabetes.

Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.

Abstract: Provided herein are compositions, systems, and methods for treating a disease, such as kidney and/or cardiovascular disease, with an agent that reduces the production of trimethylamine (TMA) or trimethylamine-n-oxide (TMAO) in a subject. In certain embodiments, the agent is: i) 3,3-dimethyl-1-butanol (DMB) or a DMB derivative or related compound, ii) acetylsalicylic acid or derivative thereof (e.g., with an enteric coating for delivery to the colon and/or cecum); iii) a flavin monooxygenase 3 (FMO3) inhibitor; iv) a gut TMA lyase inhibitor; v) an antibiotic or antimicrobial; vi) a probiotic or prebiotic; vii) an antiplatelet agent; or viii) a TMA and/or TMAO sequestering agent.

Abstract: The present invention relates to a method of treating brain cancer comprising administering a therapeutically effective substance to a patient, wherein the therapeutically effective substance comprises: (I), or a pharmaceutically acceptable salt thereof, wherein X is a moiety that can be cleaved hydrolvtically or enzymaticaily in the body of the patient in a pH-dependent manner.

Abstract: A composition for chemoembolotherapy of solid tumours comprises particles of a water-insoluble water-swellable synthetic anionic polymer and, absorbed therein an anthracycline. Suitably the polymer is a poly(vinyl alcohol) based polymer and the drug is doxorubicin.

Abstract: The present invention relates to use of a microRNA or an inhibitor thereof, and specifically, the present invention relates to use of a microRNA or an inhibitor thereof in preparing a medicament for regulating lipid metabolism or preparing a medicament for preventing or treating a disease related to lipid metabolism. The microRNA is one or more of the following: miRNA-96, miRNA-185, and miRNA-223. The present invention also relates to use of the microRNA or the inhibitor thereof in regulating the expression level of a protein related to lipid metabolism. The present invention also relates to a composition comprising the microRNA or the inhibitor thereof. The microRNA or the inhibitor thereof in the present invention can be used as a pharmaceutical component, and can be applied in preventing or treating a disease caused by lipid metabolism disorders such as hyperlipidemia, atherosclerosis, coronary heart disease or other diseases.

Abstract: The invention relates to methods and compositions for treating and preventing cardiovascular disease, including but not limited to treating and preventing endothelial dysfunction in subjects having hyperhomocysteinemia, hyperglycemia, or a combination of hyperhomocysteinemia and hyperglycemia. As endothelial dysfunction is an indicator for atherosclerosis and cardiovascular disease, this treatment has general impact for early prevention and treatment for all cardiovascular disease. In particular, the present invention relates to methods and compositions for inhibiting calpain activity.

Abstract: A nutritional composition comprised of whey protein (WP) and resistant starch (RS) designed to reduce body fat, body fat distribution and as a result lower Body Mass Index (BMI) in humans.

Abstract: The present invention provides compositions and methods for sensitizing a bacterium to an antibacterial the method comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance. Methods for killing an antibacterial-resistant bacterium comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance and exposing the bacterium to an antibacterial are also provided. The methods may also include the step of identifying the bacterium and the antibacterial resistance profile of the bacterium and tailoring the methods accordingly. Exemplary entry promoting agents provided are polyhexamethylene biguanide (PHMB) and polyhexamethyleneguanide (PHMG). Exemplary agents that inhibit antibacterial resistance are agents that bindto and inhibit antibacterial-resistance determinants such as beta-lactamases, PBP2a, NDM-1 and Vim2.

Abstract: A device for producing a hydrogen containing fluid, having a container that stores fluid which able to be used for a living organism and has water vapor permeability, a hydrogen generating system that generates hydrogen by using moisture, and a wrapping member that encloses the container and the hydrogen generating system and has low hydrogen molecule permeability. The wrapping member encloses the container and the hydrogen generating system located outside the container, and a treatment to increase humidity in a space between an outer surface of the container and an inner surface of the wrapping member is performed.

Abstract: An antibacterial composition comprising arginine bicarbonate, zinc carbonate, preferably arginine bicarbonate and zinc carbonate (ABZC), in combination, plus one or more physiologically acceptable excipients, administered for the modification of cutaneous microfloras, generally to inhibit the growth of pathogenic Staphylococcus aureus bacteria by promoting the growth of non-pathogenic Staphylococcus epidermidis bacteria.

Abstract: The present invention relates to methods for promoting dispersal of, or preventing formation of microbial biofilms, comprising: exposing a biofilm to an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; treating a surface or medium susceptible to biofilm formation with an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent; incorporating an effective amount of nitric oxide or at least one nitric oxide generating or releasing agent in a surface or medium susceptible to biofilm formation; or inducing the accumulation of one or more reactive oxygen or nitrogen species within microorganisms within said biofilm or capable of forming a biofilm. The invention also relates to methods for maintaining or enhancing or maintaining and enhancing the functioning of a biofilm, comprising exposing a biofilm to at least one nitric oxide scavenger, at least one antioxidant or at least one nitric oxide scavenger and at least one antioxidant.

Abstract: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through a combination of ex vivo gene therapy protocols and cell enchment, tumor cells are engineered to express an ? (1,3)galactosyl epitope and optionally the tumor associated antigens mesothelin and carcinoembryonic antigen. After administration of the compositions of the invention to patients, the production of increased antibody titers to certain cell-surface markers, including mesothelin, calreticulin, and carcinembryonic antigen (CEA) positively correlates with an increased overall survival.

Abstract: This invention relates to the field of therapeutics. Most specifically invention provides methods of generating in vitro engineered immune cells conditionally expressing interleukin-12 (IL-12) and one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals.

Abstract: An article, system, and method is provided for the filtration of blood wherein the blood is removed, contacted with a filter substrate operatively associated with a filter structure, and the filtered blood is subsequently returned to a receiver. Methods for removing iron from the liquid fraction of blood and for determining whether a substrate is capable of selectively retaining 2,2?-dipyrydyl (DP)-Fe2+ complexes are also disclosed.

Abstract: The present invention relates to fermentation of milk-derived nutritional compositions to increase thiol protease inhibitor activity, and uses thereof with the products obtained.

Abstract: Disclosed are cellular compositions and methods relating to the use of aqueous trehalose media to suspend cells. A trehalose-containing medium can be used to inhibit cellular clumping, for example upon dilution of more concentrated cellular preparations into the trehalose-containing medium. In certain embodiments cells, after cryopreservation and thawing, are combined with a trehalose-containing medium to prepare a clumping-inhibited cell suspension.

Abstract: An object of the present invention is to provide an extract from inflamed skins of rabbits inoculated with vaccinia virus where the quality of the extract is more stabilized and also to provide a preparation, etc. containing said extract as an active ingredient. When the amount of sulfated tyrosine contained in an extract from inflamed skins of rabbits inoculated with vaccinia virus and also contained in a preparation containing said extract as an active ingredient is used as an index, the quality of the extract and the preparation among the manufacturing lots can be warranted as a more stabilized one. In the extract from inflamed skins of rabbits inoculated with vaccinia virus and the preparation containing said extract where the quality thereof is more stabilized by such a method, the efficacy and the safety thereof are now guaranteed more strictly resulting in very high usefulness.

Abstract: Provided is a method for treatment of atopic dermatitis and infectious dermatitis with biological spa therapy. The method seeks to cure or alleviate symptoms of atopic dermatitis by bathing in a bathwater containing, as dominant bacteria, not less than 105 Bacillus bacteria per 1 mL of the bathwater.

Abstract: The present invention relates to means and methods for modulating the gut microbiota composition of a subject, preferably a human. In particular, the present invention provides an agent capable of reducing the proportion of Lachnospiraceae in the gut microbiota composition of a subject which agent is useful for promoting weight loss or preventing weight gain in a subject, preferably an obese or overweight subject. Lactobacillus rhamnosus CGMCC 1.3724 is particularly preferred as the agent provided by and used in the present invention.

Abstract: An embodiment is a method of preventing, mitigating or treating Gastroesophageal Reflux Disease (GERD) that includes administering an effective amount of a medicament comprised of the Lactobacillus bulgaricus B-30892 strain and/or bioactive compounds from its supernatant to a human to prevent, mitigate or treat GERD.

Abstract: The present invention relates to a Hericium erinaceus-containing cereal comprising grain or legume, saccharide and Hericium erinaceus, and a method for preparing the same. The Hericium erinaceus-containing cereal according to the present invention enables the Hericium erinaceus component having excellent anticancer and brain function-activating effects to be naturally taken as a meal replacement or a light meal by people of all ages and both sexes without rejection.

Abstract: The present invention relates to use of a tall oil fatty acid in enhancing rumen fermentation and/or lowering rumen methane production.

Abstract: Exemplary embodiments of the present invention provide fermented foods improving bowel functions with stercoral removal efficiency and a manufacturing method thereof. The manufacturing method of the fermented foods improving bowel functions includes a first process in which herb powder and glasswort powder placed in a cloth pouch together are heated in a potable water, and a second process in which the previously heated mixture is fermented at 20-50° C. with fermenting strain. In a third process, the previously fermented mixture may be solidified then kneaded with psyllium husk powder and the fermented liquid.

Abstract: A homogenate to be administered to a patient to inhibit and reduce increased glucose level in the blood and stimulate insulin secretion. The homogenate includes the use of different components, mainly the herb Petroselinum Crispum (parsley) to be administered to a patient at a particular dosage for a predetermined period of time depending on the severity of the case, and that effectively decreases and controls the patient's glucose levels and insulin secretion.

Abstract: Composition useful in treating and/or preventing spontaneous abortions derived from a traditional recipe of herbal medicine. The composition contains active components from three herbal medicines: total flavonoids of Cuscuta Chinensis, total flavonoids of Taxillus Sutchuenensis, total polysaccharides of Taxillus Sutchuenensis, and total saponins of Radix Dipsaci Asperoidis. This composition shows potent effects on reducing apoptosis induced by mifepristone in trophoblast cells, likely by inhibiting the expression of Bax, Caspase-9 and Caspase-3. Its effect is more significant than progesterone, one of the compounds currently used for preventing spontaneous abortions.

Abstract: Disclosed herein is a nutraceutical composition comprising dried Ziziphus mauritiana leaves, dried Lepidium sativum leaves, dried olive leaves at specific weight ratios and a specific amount of olive oil. The disclosed composition has been shown to effectively treat with minimal side effects, the common symptoms of sickle cell disease (SCD) including severe pain, bacterial infection, inflammation, wounds, fever, cough, shortness of breath. Various embodiments of methods of treating SCD patients using the same composition and methods of preparing the composition are also provided.

Abstract: A medicinal tonic has a unique combination of ingredients. The tonic is composed, proportionally, of approximately 66 fluid ounces of organic Aloe juice, 60 ounces of organic Aloe gel, 16 grams be weight of wild lapacho bark extract, and 20 milliliters each of organic hyssop, organic or wild milk thistle extract and organic, naturally farmed olive leaf extract. The ingredients produce a new and medicinal compound that prevents or alleviates natural occurring diseases or conditions and helps heal wounds and other ailments and has other salutary effects on the human body.

Abstract: The present invention refers to the use of protein kinase inhibitors and more specifically to the use of inhibitors of the protein kinase c-Jun amino terminal kinase, JNK inhibitor (poly-)peptides, chimeric peptides, or of nucleic acids encoding same as well as pharmaceutical compositions containing same, for the treatment of non-chronic or chronic inflammatory eye diseases, such as inflammatory diseases of the blephara, conjunctiva, cornea, sclera, the vitreous body, uvea, ciliary body, choroid, orbital bone, lacrimal gland, or iris, in particular wherein the inflammatory disease is selected from hordeolum, chalazion, conjunktivitis, keratitis, scieritis, episcleritis, endophthalmitis, panophtalmitis, irititis, uveitis, cyclitis, chorioiditis, orbital phlegmon, and myositis of the eye muscle etc.

Abstract: The present invention relates to inhibitors of Nox1-dependent reactive oxygen species production and their use in the treatment of disorders associated with reactive oxygen species, such as hypertension and cancer.

Abstract: Dermal fibroblasts permanently loose their ability to synthesize elastin, the major component of elastic fibers, shortly after puberty. This progressive loss of elastic fibers cannot be replaced, resulting in the physical signs of aging. The present invention provides methods and compositions containing the polyphenols ellagic acid and/or tannic acid for protection against degradation of cutaneous elastic fibers by the elastolytic enzymes. The use of ellagic acid and/or tannic acid increased the overall deposition of elastic fibers in healthy and damaged skin cells. The protection of both intra- tropoelastin and extra-cellular mature elastic fibers from proteolytic enzymes by ellagic acid and tannic acid caused an increase in the net deposition of elastic fibers. Therefore, embodiments of the present invention provide methods and composition for the treatment of skin and prevention and treatment of degradation of dermal elastic fibers.

Abstract: This disclosure pertains to a method of treating liver cancer using a peptide based on venom from a terebrid snail, terebrid variegata. The venom has a general formula of TRX3CCGCYWNGSKDVCSQSCC (SEQ ID NO. 1) and variants thereof are described.

Abstract: This document provides methods and materials related to treating liver conditions. For example, the methods and materials relating to the use of cAMP inhibitors to treat liver conditions are provided.

Abstract: The inventions describe here cover therapeutic compositions, and methods of use, for neutralizing Type I interferons in a mammal. The compositions contain a soluble Orthopoxvirus IFN-binding protein that is modified to remove the cell-binding region, and that specifically binds to Type I IFNs, and a pharmaceutically acceptable carrier or excipient. Another variation of the invention entails a novel IFN-binding protein that is modified to remove the cell-binding region and the signal sequence.

Abstract: The present invention provides methods for facilitating cleansing of the gastrointestinal tract of a patient prior to a diagnostic, surgical or therapeutic procedure. The methods can improve patient compliance, and thus, efficacy of the preparation. Specifically, the present methods make the gastrointestinal tract preparation composition palatable for the patient to consume. For example, for a patient preparing to undergo colonoscopy, the present methods make the bowel preparation solution taste significantly less salty.

Abstract: Disclosed are therapeutic, activated leukocyte conditioned supernatants, methods of making them, and methods of using the conditioned supernatants to repair or promote healing of wounds.

Abstract: It is intended to provide MSCs for transplantation that have an improved post-transplantation cell survival rate and engraftment rate and are highly safe with fewer adverse reactions, and a method for conveniently producing MSCs for transplantation having a high cell survival rate and engraftment rate. As means therefor, the present invention provides a stem cell for transplantation comprising an MSC capable of overexpressing IL-10.

Abstract: The invention relates to a process for inactivating pathological prion proteins (PrPsc) in a sample or a material which may be contaminated by a pathological prion protein, wherein the sample or the material which may be contaminated by a pathological prion protein is put into contact with at least one methionine sulfoxide reductase.

Abstract: Disclosed herein are compositions and methods for treating damage inflicted by use of a cardio-pulmonary bypass (CPB) machine, particularly excessive bleeding and multi organ failure, by administering a pharmaceutical composition comprising alpha-1 antitrypsin (AAT).

Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one mRNA comprising at least one coding region for at least one antigen from a tumour, in combination with an aqueous solvent and preferably a cytokine, e.g. GM-CSF, and a process for the preparation of the pharmaceutical composition. The pharmaceutical composition according to the invention is used in particular for therapy and/or prophylaxis against cancer.

Abstract: Recombinant attenuated Y. pseudotuberculosis mutants have been created that show efficacy as oral vaccines against plague caused by Y. pestis and Yersinosis caused by both Y. enterocolitica and Y. pseudotuberculosis. Thus, live attenuated Y. pseudotuberculosis-based vaccines can be used to prevent Yersinosis in farm animals such as swine, cattle and sheep. The palatable baits containing live attenuated Y. pseudotuberculosis-based vaccines may be acceptable methods to control plague epidemics in wild animals. The methods disclosed can also be used to generate recombinant attenuated Y. entercolitica and Y. pestis vaccine strains.

Abstract: A pharmaceutical preparation for prophylaxis against and treatment ofStaphylococcus induced infections or conditions in humans and animals, is disclosed, wherein it comprises a combination of a) one or more viable ?-Streptococcus strains chosen from the group consisting of the Streptococcus sanguis II strains having the accession numbers NCIMB 40104, NCIMB 40105, NCIMB 40106, and NCIMB 40873, the Streptococcus mitis strains having the accession numbers NCIMB 40107, and NCIMB 40874, the Streptococcus oralis strains having the accession numbers NCIMB 40875 and NCIMB 40876, the Streptococcus lactis strain L1A having the accession number NCIMB 40157, and one or more variants thereof having the same or essentially , similar effect; and b) one or more viable Lactobacillus strains chosen from the group consisting of the Lactobacillus rhamnosus strain LB21 having the accession number NCIMB 40564, the Lactobacillus plantarum strain LB3 having the accession number N DSM 17852, and the Lactobacillus plantarum strain LB7

Abstract: An oral preparation for the prophylaxis or treatment of a disease with infection by a pathogen, containing a killed lactic acid bacterium expressing, on the surface, an antigen of the pathogen, or a microparticulated form thereof, which has an average particle size of 2.68-30 ?m. An oral preparation for inducing cellular immunity to a target antigen, containing a killed lactic acid bacterium expressing the target antigen on the surface or a microparticulated form thereof, which has a particle size of 2.68-30 ?m.

Abstract: The disclosure concerns compositions containing inactivated but therapeutically active biopharmaceuticals, and methods for formulation thereof. Biopharmaceuticals are encapsulated and immobilized in dry amorphous carbohydrate-glass and irradiated for inactivation while in the dry state. The resulting compositions provide ambient-temperature stable, therapeutically active but inactivated biopharmaceuticals for use in vaccines and other applications.

Abstract: Disclosed are compositions of matter consisting of collections of nanodisks associated with polypeptide immunogens. Each said collection contains multiple epitopes of at least one immunogen. When used as a component of a vaccine, these epitopes are chosen to confer immunity, in the vaccinated subject, against a spectrum of possible infective strains of the target pathogen. This immunity is derived from the various antibodies, to the various epitopes of the immunogen, produced by the adaptive immune system of the subject in response to exposure to said vaccine. In this manner, said vaccine may confer immunity against the entire spectrum of possible infective strains of the target pathogen.

Abstract: Compositions, vaccines and methods for inducing protective immunity against Human Immunodeficiency Virus (HIV) infection are described. Heterologous vaccine combinations of one or more viral expression vectors and an isolated antigenic polypeptide induced strong protective immunity against infections by one or multiple clades of HIV.

Abstract: The present invention relates to compositions and methods that promote the induction of IL-12 in a patient. The composition includes activated allogeneic cells that are administered to a patient with a disease such as cancer. Administration of the composition skews the patient's immune response to a Th1 environment and produces detectable levels of IL-12 in the patient's plasma, without any IL-12 related toxicity.

Abstract: A novel combination comprising the MEK inhibitor N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, and/or a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and an anti-PD-L1 antibody; pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or neutralizing or inhibiting the interaction between PD-L1 and its receptor, e.g. PD-1, is beneficial, eg. cancer.